文摘
摘要目的:跟踪的纵向演化颈脊髓萎缩在多发性硬化(MS)患者的主要疾病临床表型及其临床意义,通过分析一个大型、多中心数据集获得9个欧洲网站。
背景:女士的特点是严重的颈脊髓萎缩,这可能是临床相关,有助于解释残疾进展。
设计/方法:基线3 d t1颈线扫描获得从167名健康对照组(HC)和421 MS患者(36临床孤立综合征(CIS), 202年复发缓和(名RRMS)女士,96年二次进步(spm)女士,45良性(BMS)女士和42个主要进步女士[专业])。从157年的后续扫描对象(49 HC和108 MS患者,平均随访时间= 1.1年,范围= 0.5 - -2.1年)。Whole-cervical线横截面积(CSA)是使用一个活跃的表面方法评估。基线CSA及其纵向变化HC和MS患者之间相比,临床恶化和稳定的患者,使用方差分析模型和在疾病临床表型(调整年龄、性别和地点)和配对t检验。
结果:MS患者的基线CSA较低vsHC (p < 0.001),项目组合管理系统vsHC和CIS (p < 0.001),名RRMSvs独联体(p = 0.001), spmvs百时美施贵宝(p < 0.001)和名RRMS (p < 0.001)。纵向线CSA变化在HC + 0.01% (p = 0.9)和女士−1.1% (p = 0.001),大量的时间x组交互(p = 0.04)。临床表型分析分别时,明显的脊髓组织损失被发现在名RRMS (CSA改变=−1.5%,p = 0.001)和项目组合管理系统(CSA改变=−2.0%,p = 0.05)。临床医学患者恶化发展脊髓萎缩明显高于临床稳定的女士(CSA改变=−−2.2% 0.7%,px小组互动= 0.03)。
结论:除了CIS,重要的颈脊髓萎缩表型女士被发现在所有。一年期绳萎缩是临床相关的女士和发展在不同的速率主要表型,在项目组合管理系统和名RRMS患者更严重。
研究支持:
穆罕默德Aboulwafa ECTRIMS-MAGNIMS奖学金支持的核磁共振
披露:罗卡博士已经收到个人赔偿的活动与诺华、Idec, Teva神经科学和Genzyme演讲者。Aboulwafa博士没有披露。Valsasina博士没有披露。Preziosa博士已经收到个人活动与补偿Idec,诺华和ExceMED议长。Barkhof博士已经收到个人赔偿的活动与拜耳先灵葆雅制药、Idec,赛诺菲安万特Genzyme,詹森研究,默克公司Serono,诺华,罗氏,合成纤维BV, Teva神经科学作为顾问或扬声器。Vrenken博士接到EMDSerono研究支持。米兰球迷博士没有披露。Zecca博士没有披露。博士·罗维拉已收到个人活动与Genzyme补偿,诺华,生原体,Bracco, Teva。好吃的博士已经收到个人活动与Almirall补偿,拜耳,生原体,Celgene公司,赛诺菲安万特Genzyme,默克公司诺华,罗氏公司和梯瓦制药。 Dr. Kearney has nothing to disclose. Dr. Ciccarelli has received personal compensation for activities with Novartis, Biogen and GE as a consultant. Dr. Matthews has nothing to disclose. Dr. Palace has received personal compensation for activities with Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma, Alexion and Bayer Schering as an advisor. Dr. Gallo has received personal compensation for activities with Biogen, Sanofi-Aventis, Merck Serono, Genzyme, Teva, Bayer-Schering and Novartis as a speaker along with travel grants. Dr. Bisecco has nothing to disclose. Dr. Gass has received personal compensation for activities with Biogen Idec and Novartis. Dr. Eisele has nothing to disclose. Dr. Lukas has nothing to disclose. Dr. Bellenberg has nothing to disclose. Prof. Comi has received personal compensation for activities with Novartis, Teva Pharmaceutical Ind. Ltd, Sanofi, Genzyme, Merck Serono, Bayer, Actelion Sano as a speaker, consultant or participating on an advisory board. Dr. Filippi has received personal compensation for activities with Biogen Idec, Excemed, Novartis, and Teva as a consultant and/or speaker.
